Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Operations: 2022-2025

Historic Cash from Operations for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$28.3 million.

  • Entrada Therapeutics' Cash from Operations fell 16.68% to -$28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.9 million, marking a year-over-year decrease of 815.96%. This contributed to the annual value of -$41.6 million for FY2024, which is 129.73% down from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Cash from Operations is -$28.3 million, which was up 3.99% from -$29.5 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Cash from Operations registered a high of $203.4 million during Q1 2023, and its lowest value of -$38.5 million during Q1 2025.
  • In the last 3 years, Entrada Therapeutics' Cash from Operations had a median value of -$25.5 million in 2024 and averaged $176,091.
  • In the last 5 years, Entrada Therapeutics' Cash from Operations spiked by 1,068.98% in 2023 and then tumbled by 687.57% in 2024.
  • Over the past 4 years, Entrada Therapeutics' Cash from Operations (Quarterly) stood at -$27.3 million in 2022, then soared by 85.30% to -$4.0 million in 2023, then crashed by 687.57% to -$31.6 million in 2024, then declined by 16.68% to -$28.3 million in 2025.
  • Its Cash from Operations was -$28.3 million in Q3 2025, compared to -$29.5 million in Q2 2025 and -$38.5 million in Q1 2025.